Loading...
•
Dec 31, 2023
Royalty Pharma Q4 2023 Earnings Report
Reported financial results for the fourth quarter and full year of 2023 and introduced full year 2024 guidance for Portfolio Receipts.
Key Takeaways
Royalty Pharma reported a decrease in Portfolio Receipts by 31% to $736 million for Q4 2023, which was due to accelerated Biohaven payments in Q4 2022. Royalty receipts increased by 10%, driven by cystic fibrosis franchise, Trelegy and Evrysdi, and the addition of new royalties on Spinraza.
Portfolio Receipts decreased 31% to $736 million in Q4 2023.
Royalty receipts increased 10% for the quarter.
Announced value of new transactions was $4.0 billion for full year 2023.
Transactions since 2020 expected to add approximately $1.2 billion to Portfolio Receipts in 2025.
Royalty Pharma
Royalty Pharma
Royalty Pharma Revenue by Segment
Revenue by Segment
Cystic Fibrosis Franchise Revenue
CapyFin.comTrelegy Revenue
CapyFin.comTysabri Revenue
CapyFin.comEvrysdi Revenue
CapyFin.comXtandi Revenue
CapyFin.comImbruvica Revenue
CapyFin.comPromacta Revenue
CapyFin.comTremfya Revenue
CapyFin.comCabometyx/Cometriq Revenue
CapyFin.comSpinraza Revenue
CapyFin.comTrodelvy Revenue
CapyFin.comErleada Revenue
CapyFin.comOther Products Revenue
CapyFin.com Forward Guidance
Royalty Pharma expects 2024 Portfolio Receipts to be between $2,600 million and $2,700 million, which includes expected royalty receipts growth of 5% to 9%.
Positive Outlook
- Portfolio Receipts between $2,600 million and $2,700 million
- Expected royalty receipts growth of 5% to 9%
- Guidance reflects a negligible estimated foreign exchange impact to Portfolio Receipts
- Total interest paid is anticipated to be approximately $160 million in 2024.
- Guidance assumes no major unforeseen adverse events
Challenges Ahead
- Excludes the contributions from transactions announced subsequent to the date of this press release.
- Guidance may be amended in the event it engages in new royalty transactions which have a material near-term financial impact on the company.
- Payments for operating and professional costs 8% to 9% of Portfolio Receipts
- Interest Paid $160 million
- Assumes no additional debt financing in 2024, including no drawdown on the revolving credit facility.
Revenue & Expenses
Visualization of income flow from segment revenue to net income